Cargando…

CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease

INTRODUCTION: CSF levels of established Alzheimer’s disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, William T., Watts, Kelly D., Tailor, Prashant, Nguyen, Trung P., Howell, Jennifer C., Lee, Raven C., Seyfried, Nicholas T., Gearing, Marla, Hales, Chadwick M., Levey, Allan I., Lah, James J., Lee, Eva K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758165/ https://www.ncbi.nlm.nih.gov/pubmed/26887322 http://dx.doi.org/10.1186/s40478-016-0277-8

Ejemplares similares

U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer’s disease due to autosomal dominant genetic mutations and trisomy 21
por: Hales, Chadwick M, et al.
Publicado: (2014)

Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease
por: Ping, Lingyan, et al.
Publicado: (2018)

Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease
por: Borkowski, Kamil, et al.
Publicado: (2021)

Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease
por: Ping, Lingyan, et al.
Publicado: (2020)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism
por: Borkowski, Kamil, et al.
Publicado: (2023)

Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
por: Dai, Jingting, et al.
Publicado: (2018)

Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer’s Disease
por: Guo, Qi, et al.
Publicado: (2021)

A proteomic network approach across the ALS‐FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain
por: Umoh, Mfon E, et al.
Publicado: (2017)

Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease
por: Higginbotham, Lenora, et al.
Publicado: (2020)

Machine Learning Selection of Most Predictive Brain Proteins Suggests Role of Sugar Metabolism in Alzheimer’s Disease
por: Tandon, Raghav, et al.
Publicado: (2023)

Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer’s disease-related proteins
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Fine particulate air pollution and neuropathology markers of Alzheimer’s disease in donors with and without APOE ε4 alleles – results from an autopsy cohort
por: Christensen, Grace M., et al.
Publicado: (2023)

Integrated Approaches for Analyzing U1-70K Cleavage in Alzheimer’s Disease
por: Bai, Bing, et al.
Publicado: (2014)

Differential DNA Methylation in the Brain as Potential Mediator of the Association between Traffic-related PM(2.5) and Neuropathology Markers of Alzheimer’s Disease
por: Li, Zhenjiang, et al.
Publicado: (2023)

TBK1 interacts with tau and enhances neurodegeneration in tauopathy
por: Abreha, Measho H., et al.
Publicado: (2021)

Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease
por: Donovan, Laura E, et al.
Publicado: (2013)

MicroRNA-650 Regulates the Pathogenesis of Alzheimer’s Disease Through Targeting Cyclin-Dependent Kinase 5
por: Lin, Li, et al.
Publicado: (2023)

Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer’s disease
por: Donovan, Laura E., et al.
Publicado: (2021)

Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease
por: Higginbotham, Lenora, et al.
Publicado: (2019)

Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
por: Dammer, Eric B., et al.
Publicado: (2022)

Proteomic Analysis of Hippocampal Dentate Granule Cells in Frontotemporal Lobar Degeneration: Application of Laser Capture Technology
por: Gozal, Yair M., et al.
Publicado: (2011)

Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
por: Zhou, Maotian, et al.
Publicado: (2020)

Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease
por: Johnson, Erik C. B., et al.
Publicado: (2018)

Predictors of Cognitive Decline in Healthy Middle-Aged Individuals with Asymptomatic Alzheimer’s Disease
por: Tandon, Raghav, et al.
Publicado: (2023)

Aberrant septin 11 is associated with sporadic frontotemporal lobar degeneration
por: Gozal, Yair M, et al.
Publicado: (2011)

Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease
por: Modeste, Erica S., et al.
Publicado: (2023)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease
por: Watson, Caroline M., et al.
Publicado: (2023)

Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level
por: Johnson, Erik C. B., et al.
Publicado: (2022)

TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration
por: Lee, Samuel M, et al.
Publicado: (2019)

Complement Protein Isoforms in CSF as Possible Biomarkers for Neurodegenerative Disease
por: Finehout, Erin J., et al.
Publicado: (2005)

The Georgia Memory Net: Implementation of a statewide program to diagnose and treat Alzheimer's disease and related dementias
por: Bender, Alexis A., et al.
Publicado: (2022)

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

Neuronal LR11 Expression Does Not Differentiate between Clinically-Defined Alzheimer's Disease and Control Brains
por: Sager, Kristen L., et al.
Publicado: (2012)

Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
por: Rayaprolu, Sruti, et al.
Publicado: (2020)

Development of transgenic rats producing human β-amyloid precursor protein as a model for Alzheimer's disease: Transgene and endogenous APP genes are regulated tissue-specifically
por: Agca, Cansu, et al.
Publicado: (2008)

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies
por: Mistur, Rachel, et al.
Publicado: (2009)

Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer’s Disease
por: Hsieh, Yi-Chen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hfve1iebcloml10utjnhgm58ec